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Background
Late cardiotoxicity is a known complication of anthracy-
cline therapy. CMR is the gold standard for assessment of
cardiac function, with demonstrated utility in the detec-
tion of subtle abnormalities of myocardial structure and
motion. Using conventional and novel CMR techniques,
we re-examined a cohort of late cancer survivors, pre-
viously studied with echocardiography in childhood. We
compared them concurrently to healthy controls, aiming
to characterise myocardial abnormalities in the context of
longitudinal functional data.
Methods
30 patients exposed to anthracyclines in childhood and 19
age and sex-matched controls underwent conventional
functional CMR, T1 mapping, Tissue Phase Mapping
(TPM) and detailed echocardiography. Myocardial T1
maps were obtained using a Modified Look-Locker Inver-
sion Recovery (MOLLI) sequence. Native T1 maps were
obtained in controls, and patients were given 0.15mmol/
kg gadolinium for extracellular volume (ECV) quantifica-
tion. Respiratory self-gated TPM was performed, using a
rotating golden-angle spiral acquisition with retrospective
cardiac gating. Both were acquired in the left ventricular
(LV) mid-short axis.
Results
The patients’ mean age was 31 ±5 years and they were stu-
died a median of of 25 (range 16-32) years following a
median cumulative anthracycline dose of 220 (range 90-
370) mg/m2 for either leukaemia or Wilms tumour.
Mid-term fractional shortening (FS), 8 years following
therapy had a mean value 33.1 ±5.1%. Current CMR-
derived LVEF was normal, although reduced compared
to controls (61% ±6 vs. 65% ±5, p <0.01) and correlated
negatively with cumulative anthracycline dose (R2 0.26,
p <0.01) and positively with mid-term FS (R2 0.27, p
<0.03).
Native myocardial T1 was not significantly different,
comparing patients and controls (967 ±37 vs. 960 ±37, p
0.53). Mean ECV was 0.26 ±0.04 and was higher in
patients receiving cumulative doses of >300mg/m2 (0.25
±0.02 vs. 0.28 ±0.05, p = 0.02).
TPM-derived LV radial, longitudinal and tangential
systolic velocities, and longitudinal E/A ratio were not
significantly reduced compared to controls.
Conclusions
This is the first detailed assessment of myocardial function
using novel CMR techniques in survivors, 25 years follow-
ing childhood anthracycline therapy. Mild, asymptomatic,
dose-related reduction in LVEF is seen, with no associated
change in native T1 values. Increased ECV is seen only at
cumulative doses >300mg/m2. Previous studies have
shown significantly increased ECV, a median of 8 years
post therapy. Our finding, associated with detailed myo-
cardial motion analysis, provides further insight into the
mechanisms of long-term remodeling in this specific
cohort.
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Table 1 Control and Patient group characteristics and cardiovascular MR data
VARIABLE CONTROL (n = 19) PATIENTS (n = 30) p value
Female n (%) 10 (53) 17 (57) 0.86
Current Age (years) 32 (26-39) 32 (23-42) 0.96
Height (cm) 171 ±6.3 169 ±9.2 0.3
Weight (kg) 67 ±8 75 ±21 0.1
NYHA I / II 19 (100) / 0 (0) 28 (93) / 2 (7) 0.44
Systolic BP (mmHg) 120 ±10 123 ±15 0.46
Diastolic BP (mmHg) 73 ±7 75 ±11 0.6
AML n (%) 2 (7)
ALL n (%) 23 (77)
Wilms n (%) 5 (17)
Age at diagnosis (years) 4.6 (1-15)
Time since chemo (years) 25 (16-32)
Anth Dose (mg/m2) 220 (90-370)
Radiotherapy n (%) 24 (80)
BMT n (%) 7 (23)
CARDIOVASCULAR MR DATA
LVEDV index (ml/m2) 72 ±8 73 ±12 0.92
LVESV index (ml/m2) 25 ±6 30 ±8 *0.05
LV EF (%) 65 ±5 61 ±6 *0.01
LV mass index (g/m2) 60 ±10 58 ±11 0.53
RVEDV index (ml/m2) 76 ±8 69 ±12 0.10
RVESV index (ml/m2) 29 ±6 28 ±14 0.68
RV EF (%) 62 ±4 63 ±5 0.39
MAPSE (cm) 15 ±1.1 13 ±2.6 *0.02
Left Atrial Area (cm2) 20 ±2.3 21 ±3.1 0.47
Native myocardial T1 960 ±37 967 ±37 0.53
Native blood pool T1 1484 ±76 1463±118 0.50
Extracellular volume fraction 0.26 ±0.04
Focal LGE 2 (7)
Values expressed mean mean ±SD.
LVEDV = left ventricular end diastolic volume; LVESV = left ventricular end systolic volume; LVEF = left ventricular ejection fraction; RVEDV = right ventricular end
diastolic volume; RVESV = right ventricular end systolic volume; RVEF = right ventricular ejection fraction; MAPSE = mitral annular plane systolic excursion; LGE =
Late gadolinium enhancement.
Table 2 Data comparing high and low cumulative anthracycline dose.
CARDIOVASCULAR MR DATA Low dose <300mg/m2 (n =22) High dose >300mg/m2 (n = 8) p Value
LVEDV index (ml/m2) 71 ±11 80 ±14 0.1
LVESV index (ml/m2) 28 ±8 36 ±6 *0.03
LV EF (%) 65 ±5 54 ±6 *0.01
LV Mass index (g/m2) 58 ±11 59 ±9 0.94
RVEDV index (ml/m2) 70 ±10 69 ±17 0.87
RVESV index (ml/m2) 28 ±15 26 ±7 0.77
RV EF (%) 65 ±5 62 ±2 0.46
MAPSE (cm) 13 ±2.1 13 ±4.1 0.72
Left Atrial Area (cm2) 21 ±3 21 ±4 0.94
Native T1 960 ±39 992 ±24 *0.05
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Table 2 Data comparing high and low cumulative anthracycline dose. (Continued)
Native blood pool T1 1464 ±79 1527±38 *0.05
Extracellular volume fraction 0.25 ±0.02 0.28 ±0.05 *0.02
LGE 1 (14) 1 (5)
Values expressed mean mean ±SD
LVEDV = left ventricular end diastolic volume; LVESV = left ventricular end systolic volume; LVEF = left ventricular ejection fraction; RVEDV = right ventricular end
diastolic volume; RVESV = right ventricular end systolic volume; RVEF = right ventricular ejection fraction; MAPSE = mitral annular plane systolic excursion; LGE =
Late gadolinium enhancement
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